News

EP says no to patents on breeding
Enlarge image

PolicyEU

EP says no to patents on breeding

11.05.2012 - The European Parliament has adopted a non-binding resolution to exempt conventionally-bred plants or animals from patents.

Strasbourg – Although these patents are an important tool for the transfer of technology, the Parliament fears that "excessively broad patent protection can hamper innovation and progress and become detrimental to small and medium breeders by blocking access to animal and plant genetic resources". Therefore, the Parliament called on the European Patent Office to exclude products derived from conventional breeding, such as anti-carcinogenic broccoli or high-yield dairy cows, and all conventional breeding methods from patenting. It also wants the Commission and the Member States to ensure that the EU continues to exempt breeders from its patent law on plant and animal breeding. The non-legislative resolution was adopted by 354 votes to 192, with 22 abstentions.

“This is a huge success for all farmers, breeders and consumers who are concerned about the monopolisation of our food resources,” says Ruth Tippe from the coalition “No Patents On Seeds!“. Despite this, industry experts warn, that the motion might hamper the development of genetically modified crops or animals. The European Parliament therefore asked the European Commission to report “on the development and implications of patent law in the field of biotechnology and genetic engineering“ and to examine the impact of the patenting of breeding methods on the breeding and food industry.

The relevant European patent law dates from 1998. De jure it is impossible to receive patent protection for conventionally bred or genetically modified plant and animal varieties. Environmental Groups such as No Patents On Seeds claim that there is a loophole however: In the past, the European Patent Office protected gm-modified crops on the grounds that only the breeding process could not be patented, but the product regardless.

http://www.european-biotechnology-news.com/news/news/2012-02/ep-says-no-to-patents-on-breeding.html

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Aachen

Biomedica 2016

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • ZEALAND PHARMA (DK)130.50 DKK11.06%

FLOP

  • BIOFRONTERA (D)2.84 EUR-4.70%
  • CHRONTECH PHARMA (S)0.34 SEK-2.86%
  • PHOTOCURE (N)41.50 NOK-2.35%

TOP

  • THERAMETRICS (CH)0.03 CHF50.0%
  • GALAPAGOS (B)52.23 EUR30.5%
  • NICOX (F)10.89 EUR26.3%

FLOP

  • MOBERG PHARMA (S)38.70 SEK-21.8%
  • BIONOR PHARMA (N)0.70 NOK-21.3%
  • BIOCARTIS GROUP NV (B)8.32 EUR-18.4%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)29.50 SEK1853.6%
  • NICOX (F)10.89 EUR485.5%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.95 SEK-87.8%
  • BB BIOTECH (D)44.62 EUR-84.6%
  • BIOTEST (D)17.10 EUR-77.8%

No liability assumed, Date: 26.05.2016